Challenges and advances in the development of inhalable drug formulations for cystic fibrosis lung disease. - Wikidata - wikimedia - TriplyDB

Challenges and advances in the development of inhalable drug formulations for cystic fibrosis lung disease.

Challenges and advances in the development of inhalable drug formulations for cystic fibrosis lung disease.

http://www.wikidata.org/entity/Q37849777

about

PEI-engineered respirable particles delivering a decoy oligonucleotide to NF-κB: inhibiting MUC2 expression in LPS-stimulated airway epithelial cells Engineered PLGA nano- and micro-carriers for pulmonary delivery: challenges and promises.Pseudomonas aeruginosa infection in cystic fibrosis lung disease and new perspectives of treatment: a review.Core-shell nanocarriers for cancer therapy. Part I: biologically oriented design rules.Synthesis and Characterization of Nanocomposite Microparticles (nCmP) for the Treatment of Cystic Fibrosis-Related Infections Phospholipids in pulmonary drug delivery Recent Developments in Inhaled Triazoles Against Invasive Pulmonary Aspergillosis

P2860

Q28484221-ECE728EC-CF47-4346-B638-5C9AFEEE7B19 Q38033610-C8C87C40-F12D-407E-9E6D-ABCF3F3F34D9 Q38101836-538E50F4-0D37-41DF-AADE-5905770F18D8 Q38169195-2E0F18F0-0BDB-42BB-A106-E0DCD85E07AB Q40709327-2CBFF9A4-B0D2-4C9F-A12B-961F8D5E6336 Q59089495-0E53DF58-B9B6-4E5A-A10C-15C41CD39105 Q59089511-C8E6A3D8-9464-4DDA-9C7A-EC88C8EE4936

P2860

Challenges and advances in the development of inhalable drug formulations for cystic fibrosis lung disease.

http://www.wikidata.org/entity/Q37849777

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 05 March 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Challenges and advances in the ...... cystic fibrosis lung disease.

@en

Challenges and advances in the ...... cystic fibrosis lung disease.

@nl

type

label

Challenges and advances in the ...... cystic fibrosis lung disease.

@en

Challenges and advances in the ...... cystic fibrosis lung disease.

@nl

prefLabel

Challenges and advances in the ...... cystic fibrosis lung disease.

@en

Challenges and advances in the ...... cystic fibrosis lung disease.

@nl

P1433

Q37849777-C1CDDA08-BDA6-4EE7-8575-2CF906438357

P1476

Q37849777-B2AF66B9-F549-474E-81E7-99C197560197

P2093

Q37849777-4A875E17-EE2D-480F-9136-02F9E3039140

Q37849777-6C6A23B7-BEA1-4EE3-9668-3C8F821E5730

Q37849777-A2AAAC2B-F682-4916-8A0D-4CD458504457

Q37849777-CB806CD5-BE8B-4B6A-8642-116F307AD00C

P2860

Q37849777-008397E9-CA4C-4DF5-8434-CE2BD8DBD3D0

Q37849777-013433AD-B7F4-4C46-9ED8-2EB0EA14E96B

Q37849777-039590F9-1B00-407B-A239-8CC45CEB76A6

Q37849777-03C41C80-7D15-4D62-926C-DA30607A0276

Q37849777-041AC5BB-601F-44A7-8602-72FCDBC62071

Q37849777-0484BB66-BA06-4635-8D70-8393C66C87F6

Q37849777-04E33CB2-54EB-4AAC-B0A2-1A9BD4EE2CD7

Q37849777-07A92B91-3255-4C98-A712-5F315FFFC0BC

Q37849777-07F9D9C4-C76C-4023-AA75-2FE30A7E3EE6

Q37849777-09F3BF12-981C-4609-937C-26F7E9950E6D

P304

Q37849777-E63CE10F-BE03-4866-A186-E261403F05D4

P31

Q37849777-A93ECF50-1715-4283-8317-C1CBC458C6CB

P356

Q37849777-D4C640D2-8B73-4BBD-A93E-48E8C5E3B61D

P407

Q37849777-F26E6098-4A17-40D6-80DD-23C273361023

P433

Q37849777-60856453-D316-48E0-8E96-4F2B002C246A

P478

Q37849777-9615A5A1-9E88-49D9-BB0E-A9D647B52CA5

P577

Q37849777-57E553EE-E4EE-4A74-9F0E-8DEDFD9D3C8F

P5875

Q37849777-EDA8C028-70A7-47BE-9C0A-6B1B0A5D3FF4

P698

Q37849777-1CFCD69E-188E-4665-80B5-472E0AF4644F

P921

Q37849777-7D49BCD9-C428-4F20-A311-BA72C17F4D4B

P356

17425247.2011.561310

P1433

Expert Opinion on Drug Delivery

P1476

Challenges and advances in the ...... cystic fibrosis lung disease.

@en

P2093

Basma M Ibrahim

http://www.w3.org/2001/XMLSchema#string

Michael D Tsifansky

http://www.w3.org/2001/XMLSchema#string

Yan Yang

http://www.w3.org/2001/XMLSchema#string

Yoon Yeo

http://www.w3.org/2001/XMLSchema#string

P2860

Cystic Fibrosis Pulmonary Guidelines

Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation

Micro- and macrorheology of mucus

Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770

Neutrophil enhancement of Pseudomonas aeruginosa biofilm development: human F-actin and DNA as targets for therapy

Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report

Patterns of GI disease in adulthood associated with mutations in the CFTR gene

Altering mucus rheology to"solidify" human mucus at the nanoscale

Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA

Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer

P304

451-466

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/17425247.2011.561310

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2011-03-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50286701

http://www.w3.org/2001/XMLSchema#string

P698

21375469

http://www.w3.org/2001/XMLSchema#string

P921

cystic fibrosis